FDA publishes Q&A Paper "Use of Electronic Informed Consent"

Recommendation
18-20 November 2025
Heidelberg, Germany
GMP and FDA Compliance in Pharmaceutical Development and IMP Manufacturing
On December 14, 2016, the U.S. Food and Drug Administration (FDA) released a Questions and Answers (Q&A) guidance on the use of electronic informed consent in clinical investigations.
FDA says that the guidance document was developed to enhance human subject protection and reduce regulatory burden. The guidance provides recommendations on the use of electronic systems and processes that may employ multiple electronic media (e.g. text, graphics, audio, video, podcasts, passive and interactive Web sites, biological recognition devices, and card readers) to convey information related to the study and to obtain and document informed consent for both HHS (Department of Health and Human Services) -regulated human subject research and FDA-regulated clinical investigations of medical products, including human drug and biological products, medical devices, and combinations thereof.
The Q&A document provides recommendations on procedures that may be followed when using an electronic informed consent (eIC) to help:
- Ensure protection of the rights, safety, and welfare of human subjects,
- Facilitate the subject`s comprehension of the information presented during the eIC process,
- Ensure that appropriate documentation of consent is obtained when electronic systems and processes that may employ multiple electronic media are used to obtain informed consent,
- Ensure the quality and integrity of eIC data included in FDA applications and made available to FDA during inspections.
The document contains the following 16 questions (and corresponding answers):
- How should information in the eIC be presented to the subject?
- How and where may the eIC process be conducted?
- How and when should questions from subjects be answered?
- What steps may be taken to facilitate the subject’s understanding of the information being presented?
- What steps may be taken to convey additional information, including significant new findings, to the subject during the course of the research?
- How can electronic signatures be used to document eIC?
- What methods may be used to verify the identity of the subject who will be electronically signing an eIC for FDA-regulated clinical investigations?
- What special considerations should be given to the use of eIC for pediatric studies?
- Should subjects receive a copy of their eIC and have easy access to the materials and information presented to them in their eIC?
- What steps can be taken to help ensure privacy, security, and confidentiality of the eIC information?
- Can HIPAA (Health Insurance Portability and Accountability Act of 1996) authorizations for research, which are frequently combined with informed consent documents, be obtained electronically?
- What eIC materials should the investigator submit to the institutional review board (IRB)?
- What are the IRB’s responsibilities in the eIC process?
- What eIC documentation does FDA require for submission with applications?
- What steps can be taken to ensure the system archives the eIC materials appropriately for FDA-regulated clinical investigations?
- What materials or documents will FDA require during an inspection?
For more information please see the FDA Guidance for Institutional Review Boards, Investigators, and Sponsors: "Use of Electronic Informed Consent Questions and Answers".
Related GMP News
03.04.2025Update on the ICH M11 CeSHArP Technical Specification
03.04.2025EU Map to Clinical Trials
03.04.2025EMA Concept Paper on Model Informed Drug Development
20.03.2025End of the Transition Period for Clinical Trials
11.02.2025Final ICH E6(R3) Guideline on GCP released
11.02.2025FDA issues Draft Guidance on Handling Protocol Deviations in Clinical Trials